Paul Moore

Company: Zymeworks

Job title: Chief Scientific Officer

Seminars:

Leveraging AzymetricTM to Optimally Format T-Cell Engagers & Bispecific ADCs 2:15 pm

Azymetric provides a robust Fc heterodimer solution enabling high throughput functional screening of multispecific antibody panels to select those optimally formatted for a therapeutic application The most advanced Azymetric molecule, zanidatamab, a bi-paratopic anti-HER2 antibody undergoing pivotal clinical studies, exemplifies the opportunity afforded to enhance antitumor responses beyond that achieved through combination of antibody components…Read more

day: Day One